✦ LIBER ✦

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

✍ Scribed by Andrea Necchi; Luigi Mariani; Nadia Zaffaroni; Lawrence H Schwartz; Patrizia Giannatempo; Flavio Crippa; Carlo Morosi; Rodolfo Lanocita; Teodoro Sava; Cinzia Ortega; Caterina Messina; Cosimo Sacco; Marzia Pennati; Maria G Daidone; Nicola Nicolai; Filippo De Braud; Alessandro M Gianni; Roberto Salvioni

Book ID: 119608946
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 223 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70294-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tremelimumab for patients with chemother

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

✍ Calabrò, Luana; Morra, Aldo; Fonsatti, Ester; Cutaia, Ornella; Amato, Giovanni; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 431 KB

Ipilimumab and fotemustine in patients w

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

✍ Anna Maria Di Giacomo; Paolo A Ascierto; Lorenzo Pilla; Mario Santinami; Pier Fr 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 177 KB

1123 Activity of pazopanib in chemoresis

1123 Activity of pazopanib in chemoresistant patients with germ cell tumours (GCT): Early findings of the open-label, single-group, phase 2 pazotest-01 trial

✍ Necchi, A.; Mariani, L.; Giannatempo, P.; Nicolai, N.; Farè, E.; Piva, L.; Biaso 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 200 KB

Phase 2 trial of sorafenib in patients w

Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J. R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 3 views

PF-03446962, a fully-human monoclonal an

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

✍ Necchi, A.; Giannatempo, P.; Mariani, L.; Farè, E.; Raggi, D.; Pennati, M.; Zaff 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 172 KB

Phase 2 trial of pemetrexed disodium and

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Matthew M. Cooney; George Wilding; Bruce J. Roth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia